OncoMatch/Clinical Trials/NCT03999723
Combining Active and Passive DNA Hypomethylation
Is NCT03999723 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for myelodysplastic syndromes.
This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the effectiveness of epigenetic therapy in patients with higher-risk myeloid malignancies, who are not candidates for allogeneic hematopoietic stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylating agent
Prior therapy with hypomethylating agents
Cannot have received: radiation therapy
Exception: therapy-related MDS eligible if no radiation or chemotherapy for six months
Therapeutic radiation or chemotherapy within the past 6 months
Cannot have received: chemotherapy
Exception: therapy-related MDS eligible if no radiation or chemotherapy for six months
Therapeutic radiation or chemotherapy within the past 6 months
Lab requirements
Liver function
total serum bilirubin ≤1.5 × uln, serum alanine transaminase ≤3 × uln, no chronic hepatitis with decompensated cirrhosis
Cardiac function
no severe cardiac disease (nyha class 3-4)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03999723 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hypomethylating agent, radiation therapy, chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify